This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Certoparin in Renal Patients Undergoing Hemodialysis (MEMBRANE)

This study has been completed.
Information provided by (Responsible Party):
Novartis Identifier:
First received: July 27, 2010
Last updated: July 9, 2012
Last verified: July 2012
This study will assess the efficacy, safety and pharmacokinetics of certoparin when used to prevent clotting during hemodialysis.

Condition Intervention Phase
Renal Dialysis Drug: Certoparin Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Multi-center, Prospective, Open-label, 8-weeks Study to Investigate the Efficacy, Safety and Pharmacokinetics of Certoparin (3000 IU Anti-Xa Bolus, With the Option to Titrate Dose)in the Prophylaxis of Clotting in the Extracorporeal Circuit in Patients Undergoing Chronic Hemodialysis

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Number of patients requiring uptitration [ Time Frame: Week 8 ]

Secondary Outcome Measures:
  • Pharmacokinetics of Certoparin [ Time Frame: Day 1, Week 4 ]
  • Safety and tolerability of Certoparin [ Time Frame: 8 weeks ]

Enrollment: 109
Study Start Date: November 2010
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Certoparin Drug: Certoparin


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients requiring hemodialysis
  • Patients requiring anticoagulation therapy during hemodialysis
  • Written informed consent

Exclusion Criteria:

  • Hypersensitivity to study medication
  • Genetic abnormality or disease of clotting system
  • Prior major surgery or bleeding
  • Other protocol-defined inclusion/exclusion criteria may apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01179620

Novartis Investigative Site Darmstadt
Darmstadt,, Germany
Novartis Investigative Site Elsenfeld
Elsenfeld, Germany
Novartis Investigative Site Flensburg
Flensburg, Germany
Novartis Investigative Site Heringen
Heringen, Germany
Novartis Investigative Site Hoyerswerda,
Hoyerswerda, Germany
Novartis Investigative Site Kronach
Kronach, Germany
Novartis Investigative Site Magdeburg
Magdeburg, Germany
Novartis Investigative Site München
München, Germany
Novartis Investigative Site Münster
Münster, Germany
Sponsors and Collaborators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Novartis Identifier: NCT01179620     History of Changes
Other Study ID Numbers: CMEX839BDE06
Study First Received: July 27, 2010
Last Updated: July 9, 2012

Keywords provided by Novartis:
Hemodialysis, Certoparin

Additional relevant MeSH terms:
Heparin, Low-Molecular-Weight
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on June 23, 2017